Thus, the examination of p300 expression by IHC could be used as an additional tool in identifying those patients at risk of NPC progression; p300 expression analysis may also be useful in optimizing individual NPC therapy management: favoring a more aggressive regimen in tumors with a high expression of p300. The gene discussed is EP300; the disease is nasopharyngeal carcinoma.